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Abstract
Obesity is associated with a state of chronic low grade inflammation that plays an important role in the development of
insulin resistance. Tumor progression locus 2 (Tpl2) is a serine/threonine mitogen activated protein kinase kinase kinase
(MAP3K) involved in regulating responses to specific inflammatory stimuli. Here we have used mice lacking Tpl2 to examine
its role in obesity-associated insulin resistance. Wild type (wt) and tpl2
2/2 mice accumulated comparable amounts of fat and
lean mass when fed either a standard chow diet or two different high fat (HF) diets containing either 42% or 59% of energy
content derived from fat. No differences in glucose tolerance were observed between wt and tpl2
2/2 mice on any of these
diets. Insulin tolerance was similar on both standard chow and 42% HF diets, but was slightly impaired in tpl2
2/2 mice fed
the 59% HFD. While gene expression markers of macrophage recruitment and inflammation were increased in the
white adipose tissue of HF fed mice compared with standard chow fed mice, no differences were observed between wt
and tpl2
2/2 mice. Finally, a HF diet did not increase Tpl2 expression nor did it activate Extracellular Signal-Regulated Kinase
1/2 (ERK1/2), the MAPK downstream of Tpl2. These findings argue that Tpl2 does not play a non-redundant role in obesity-
associated metabolic dysfunction.
Citation: Lancaster GI, Kowalski GM, Estevez E, Kraakman MJ, Grigoriadis G, et al. (2012) Tumor Progression Locus 2 (Tpl2) Deficiency Does Not Protect against
Obesity-Induced Metabolic Disease. PLoS ONE 7(6): e39100. doi:10.1371/journal.pone.0039100
Editor: Franc ¸ois Blachier, National Institute of Agronomic Research, France
Received September 14, 2011; Accepted May 18, 2012; Published June 11, 2012
Copyright:  2012 Lancaster et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by grants from The National Health and Research Council of Australia (NHMRC Project Grant No’s 526619 and 586636)
to GIL and MAF, (Program 257502 and Project 543141) to SG and from the Leukemia and Lymphoma Society (SCOR 7015) to SG. SG and MAF are Principal
Research Fellows of the NHMRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No
additional external funding received for this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: graeme.lancaster@bakeridi.edu.au (GIL); banerjee@burnet.edu.au (AB)
Introduction
Obesity is associated with a state of chronic low grade
inflammation that is believed to be important in the development
of insulin resistance [1]. Research over the last decade has
identified numerous events critical to the induction of inflamma-
tion in models of nutrient oversupply [1]. The accumulation of
particular lipids [2,3], the generation of reactive oxygen species
[4], organelle stress [5,6] and the activation of lipid-responsive
transmembrane receptors [7,8] are amongst a multitude of stimuli
that have been suggested to link excess nutrient availability to the
induction of inflammation. However, regardless of the precise
mechanisms by which nutrient-mediated inflammation is initiated,
a commonality exists in both the signaling pathways that are
activated and the gene products that are up-regulated [1].
Two key intracellular signalling cascades that promote inflam-
mation in response to a wide array of environmental stimuli,
including nutrient oversupply, are NF-kB and the Mitogen-
Activated Protein Kinases (MAPK). Consistent with the impor-
tance of these pathways in metabolic disease, conditional
inactivation of the Inhibitor of kappa-B kinase b (IKKb), the key
activator of the classical NF-kB pathway, and the MAPK c-Jun N-
terminal kinase (JNK) in metabolically important sites including
adipose tissue [9], skeletal muscle [10] and liver [11] as well as in
immune and inflammatory mediators like macrophages [11],
prevents obesity-associated inflammation and protect against
insulin resistance. Activation of the NF-kB and Jun transcription
factors by IKKb and JNK which leads to the up-regulation of the
pro-inflammatory genes tnf, il6, il1b and ccl2 is central to this
process [1]. MAP kinases activated by obesity may also target key
components of the insulin signaling cascade, resulting in insulin
resistance [1].
Tumor progression locus 2 (Tpl2) also referred to as COT
(Cancer Osaka Thyroid), is a serine threonine mitogen activated
protein kinase kinase kinase [12] highly expressed in hemopoietic
cells that specifically activates ERK 1 and 2 via the MAP kinase
kinasesMKK1/2[13].InactiveTpl2ispartofacomplexwithA20-
binding inhibitor of NF-kB-2 (ABIN2) and p105 NF-kB1, the
precursor for thep50NF-kB1transcription factor.Tpl2 isactivated
by multiple pro-inflammatory stimuli including lipopolysaccharide
(LPS), tumour necrosis factor a (TNFa) and IL-1b [14,15] via a
multi-step process initiated by the IKKb catalysed phosphorylation
dependent degradation of p105 [16,17]. Consistent with the
importance of Tpl2 in inflammatory responses, tpl2
2/2 mice are
resistant to lipopolysaccharide (LPS)/D-galactosamine-induced
endotoxic shock, an effect due to an ERK-dependent post-
transcriptional regulation of TNFa [12]. The role of Tpl2 in
regulating ERK-dependent inflammatory processes prompted two
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39100recentstudiesthatinvestigatedtheroleofTpl2inobesity-associated
metabolic disorders [18,19]. These reports show that loss of Tpl2
function prevents high fat (HF) diet-induced adipose tissue and liver
inflammation plus HF diet-induced insulin resistance, the later
potentially via a reduction in ERK-mediated insulin receptor
substrate 1 (IRS1) serine phosphorylation. Our long standing
interests in the role of Tpl2 in inflammation [13,16,20] and also
inflammation in diet-induced metabolic disease [21–23], prompted
an independent examination of its potential role in mediating the
deleterious metabolic responses induced by a HF diet. Using a
mutant mouse model lacking Tpl2, we have failed to find any
significant role for Tpl2 in regulating obesity-associated metabolic
disorders.
Results
Male Tpl2-deficient (tpl2
2/2) and wt mice were fed either a high
fat (42% calories by energy content derived from fat) or standard
laboratory chow (8% calories by energy content derived from fat)
diet for 16 weeks, commencing at 8 weeks of age. While both
standard chow and HF-fed tpl2
2/2 mice, plus the wt standard
chow fed mice contain 8 mice per group, in the wt HFD group one
mouse did not gain any fat mass during the 16 week HF diet and
was excluded from all subsequent analysis. Data from this group
therefore represents 7 mice.
Mice fed a HF diet containing 42% calories by energy from fat
for 16 weeks were approximately 9 g heavier than standard chow
fed animals (Figure 1A), a difference entirely attributable to an
increase in fat mass (Figure 1B, C and D). No statistically
significant differences in fat mass were observed between the wt
and tpl2
2/2 mice on either the standard chow or HF diet. To
examine metabolic control in wt and tpl2
2/2 mice, we initially
determined plasma glucose and insulin levels following a 5 h fast.
Fasting plasma glucose levels were significantly higher in tpl2
2/2
mice fed a chow diet (Figure 2A). Furthermore, fasting plasma
insulin levels were significantly lower in tpl2
2/2 mice on a
standard chow diet (Figure 2B). We next determined glucose and
insulin tolerance in wt and tpl2
2/2 mice fed a standard chow diet.
While we observed the expected increases and decreases in plasma
glucose over a 2 hr time course following the IP injection of
glucose and insulin respectively, no differences were observed for
either glucose or insulin tolerance between the two genotypes
(Figures 2C and D). Of note, while plasma glucose levels during
the GTT are slightly higher in the tpl2
2/2 mice, this effect is
entirely attributable to the elevated basal glucose levels observed in
these animals. Therefore, when the incremental area under the
glucose curves were calculated (Figure 2C; inset), no significant
differences were observed in glucose tolerance (p value of 0.38)
between the two genotypes.
Next, we examined the effects of HF diet (42% calories by
energy content derived from fat) on metabolic control in wt and
tpl2
2/2 mice. Consistent with the data observed in the standard
chow fed animals, basal plasma glucose levels following a 5 h fast
were significantly higher in tpl2
2/2 mice compared to wt mice
(Figure 3A). While fasting plasma insulin levels tended to be lower
in the tpl2
2/2mice, this difference did not reach statistical
significance (Figure 3B). Importantly, when we determined glucose
and insulin tolerance, no significant differences were observed
between wt and tpl2
2/2 mice (Figure 3C and D). Again, similar to
our observation in the standard chow fed mice, the plasma glucose
levels during the GTT are slightly higher in the tpl2
2/2 mice.
However, these differences are again attributable to an increase in
fasting basal glucose levels and when the incremental area under
the glucose curve is calculated (Figure 3C; inset) no differences are
observed in glucose tolerance between the genotypes (p value of
0.98).
Our metabolic data strongly argued that Tpl2 plays no role in
regulating metabolic responses in either standard chow or HF fed
mice. Nonetheless, we performed an analysis of white adipose
tissue (epididymal fat depot) to determine the expression of a
number of genes that serve as indicators of macrophage
recruitment and inflammation, factors that are known to be
associated with obesity and implicated in the development of
insulin resistance. The expression of emr1 (also known as F4/80), a
general macrophage marker, itgax (also known as CD11c), a
marker of pro-inflammatory macrophages important in the
development of insulin resistance [24], and the expression of the
pro-inflammatory cytokine tnf, were all significantly increased in
HF fed mice, relative to standard chow fed mice (Figure 4).
However, no statistically significant differences were observed
between wt and tpl2
2/2 mice on either the standard chow or HF
diets.
Another published report showed that Tpl2 expression is up-
regulated in adipose tissue of mice on a HF diet [18]. Contrary to
their findings, we observe similar Tpl2 protein levels and mRNA
expression in wt mice regardless of the fat content in the diet
(Figure 5A and B). As described above, the primary substrates of
Tpl2 are MKK1 and MKK2 [17]. Phosphorylation of MKK1/2
by Tpl2 promotes the subsequent phosphorylation and activation
of ERK1/2. We, therefore, determined the activation status of
ERK1/2, a key target of Tpl2, in the adipose tissue of wt and
tpl2
2/2 mice on standard chow and HF diets. We observed no HF
diet-induced increases in ERK1/2 phosphorylation (Figure 5C),
arguing against a prominent role for Tpl2 in mediating ERK
activation in response to diet in vivo. This lack of difference
between standard chow and HF fed mice demonstrates that the
Tpl2 signalling pathway is not activated by HF feeding/obesity
and, therefore, argues against a significant role for Tpl2 in obesity-
associated metabolic dysfunction.
In contrast to the results described above, a previous report
demonstrated that tpl2
2/2 mice fed a HF diet containing 60% of
calories derived from fat were protected from the development of
obesity-associated insulin resistance [19]. A key difference between
this previous study and the current work is the fat content of the
HF diet, 60% versus 42%. To determine whether differences in
the fat content of the HF diet could explain the divergent results
between our study and the published report [19], we fed wt and
tpl2
2/2 mice a HF diet containing 59% of calories derived from
fat. Commencing at approximately 8 weeks age wt (n=10) and
tpl2
2/2 (n=9) mice were fed a HF diet containing 59% of calories
from fat for 16 weeks. This protocol is very similar to that used in
the previous study [19] where mice began the HF diet at 6 weeks
of age and were fed for 17 weeks. After 16 weeks of HF feeding wt
and tpl2
2/2 mice had gained 9.8 g and 8.8 g of fat mass
respectively, figures very similar to that achieved with the 42% HF
diet (Figure 1C; wt 8.6 g, tpl2
2/29.0 g). As shown in Figure 6A,
the percentage of fat mass at the end of the 16 week HF diet was
not different between wt and tpl2
2/2 mice and was very similar to
that achieved with the 42% HF diet (Figure 1D). Consistent with
the results from the standard chow and 42% HF diet, tpl2
2/2 mice
fed a 59% HF diet displayed fasting hyperglycaemia and
hypoinsulinaemia relative to wt mice (Figures 6B and C). Similar
to the data obtained with the 42% HF diet, tpl2
2/2 mice fed on
the 59% HFD had higher peak blood glucose concentrations at
several time points during the GTT compared to wt mice
(Figure 6D). However, these differences are primarily reflective
of the higher basal blood glucose concentration and when the
incremental area under the curve is calculated overall glucose
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2/2 mice (Figure 6D;
inset). Interestingly, when we assessed insulin tolerance, we
observed a mild but significant impairment in the ability of insulin
to lower blood glucose in the tpl2
2/2 mice compared to the wt
mice (Figure 6E).
Discussion
Given the previously described roles for Tpl2 in regulating
responses to various inflammatory stimuli, we hypothesised that
Tpl2 deletion may protect against the development of obesity-
associated metabolic dysfunction. Using a Tpl-2 deficient mouse
strain, our collective findings demonstrate that Tpl2 plays no
significant role in the development of the deleterious metabolic
consequences associated with a HF diet. Specifically, tpl2
2/2 and
wt mice accrue similar levels of body fat, irrespective of whether
they are fed a HF diet containing 42% or 59% of calories from
fat, and exhibit comparable glucose and insulin tolerance over
the course of a 16 week HF diet. Markers of macrophage
recruitment and inflammation following the 42% HF diet, while
elevated relative to standard chow fed mice, were comparable
between tpl2
2/2 and wt mice. Finally, similar levels of Tpl2
expression and the lack of ERK1/2 activation in adipose tissue
when comparing standard chow and HF fed mice, suggests that
the Tpl2 signaling pathway is not activated by high fat feeding-
induced obesity. Collectively, our results argue against a non-
redundant role for Tpl2 in the development of obesity-associated
metabolic dysfunction.
The results of our study are in contrast with a recent report [19]
and do not support another study that hypothesised a role for Tpl2
in the adipose tissue dysfunction associated with obesity [18]. One
of these previous studies [19] used the same strain of tpl2
2/2 mice
as that used in the work reported here and, therefore, these
phenotypic differences must be attributable to experimental
variables that differ between the different studies [19]. In our
initial experiments we used a HF diet containing 42% of calories,
which contrasted with that used by Perfield and colleagues who
used a HF diet containing 60% of calories derived from fat.
Comparison of the data obtained in our study using the 42% HF
diet and the 60% HF diet used by Perfield and colleagues shows
that the effectiveness of these two diets, with respect to the
development of obesity, was very comparable. Nonetheless, it is
possible that the use of a diet containing significantly more fat may
have provided a greater inflammatory stimulus that breached a
threshold for Tpl2 activation, thereby revealing a role for Tpl2 in
the development of obesity-associated inflammation and insulin
resistance. In support of this hypothesis, while we observed no
effect of HF feeding on ERK1/2 activation, Perfield et al [19] did
report a dietary effect on the status of ERK1/2 phosphorylation.
They demonstrated that this HF diet-induced ERK1/2 activation
is reduced in the tpl2
2/2 mice, suggesting that the increase in
ERK1/2 phosphorylation following HF diet is Tpl2 dependent.
Therefore, it is possible that in response to a diet containing a very
high fat content, Tpl2 signalling may be activated and under such
conditions deletion of Tpl2 may protect against the development
of obesity-associated dysfunction. To definitively address this issue
we performed a second set of experiments using a HF diet
containing 59% of calories derived from fat. Consistent with our
own data using the 42% HF diet, deletion of Tpl2 did not protect
mice from the deleterious metabolic consequences of the HF diet.
Instead, there was a trend towards Tpl2 deletion exacerbating the
effects of the HF diet, i.e. impaired insulin tolerance, compared to
Figure 1. wt and tpl2
2/2 mice were fed either standard chow or high fat diets for 16 weeks. (A) Total body mass. (B and C) Lean and fat
mass were determined by Echo MRI. (D) Percentage fat mass. Data presented are mean 6 SEM. All groups are n=8 with the exception of the HF fed
wt group which is n=7. * denotes statistically significant dietary main effect between standard chow (C) and high fat (HF) diets.
doi:10.1371/journal.pone.0039100.g001
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Perfield and colleagues differ. Environmental conditions such as
being housed in different animal facilities may potentially explain
this discrepancy.
Somewhat unexpectedly, we observed higher fasting plasma
glucose levels in both standard chow and 42% and 59% HF fed
tpl2
2/2 mice when compared with the wt controls. Indeed, in
the standard chow and 59% HF fed tpl2
2/2 mice, we also
observed lower fasting plasma insulin levels; a similar trend was
also observed on the 42% HF diet. Although these data are
consistent with a pancreatic insufficiency, general islet morphol-
ogy was similar in wt and tpl2
2/2 mice (Figure S1). More
importantly, when challenged with a glucose load, both
standard chow and 42% and 59% HF fed tpl2
2/2 mice were
equally tolerant and cleared the glucose bolus as effectively as
wt mice arguing against any pancreatic insufficiency in the
tpl2
2/2 animals. It remains unclear why the tpl2
2/2 display
basal fasting hyperglycaemia.
In summary, our findings do not support a role for Tpl2 in HF
diet-induced metabolic dysfunction. Consistent with this, we do
not observe any evidence of activation of the Tpl2 pathway in
adipose tissue of HF fed wt mice. The conclusions of our study are
in contrast to two previous reports that suggest an important role
for Tpl2 in mediating obesity-induced inflammation and insulin
resistance. Therefore, we believe that a more rigorous analysis on
the role Tpl2 in human metabolic syndrome should be carried out
before embarking on targeting Tpl2 for improvement of the
metabolic state in obesity.
Figure 2. wt (n=8) and tpl2
2/2 (n=8) mice were fed a standard
chow diet for 16 weeks. (A) Fasting plasma glucose. (B) Fasting
plasma insulin. (C) Glucose tolerance test. (D) Insulin tolerance test. In C,
the inset graph is the incremental area under the curve. Data presented
are mean 6 SEM. * denotes statistically significant difference between
wt and tpl2
2/2.
doi:10.1371/journal.pone.0039100.g002
Figure 3. wt (n=7) and tpl2
2/2 (n=8) mice were fed a 42% HF
diet for 16 weeks. (A) Fasting plasma glucose. (B) Fasting plasma
insulin. (C) Glucose tolerance test. (D) Insulin tolerance test. In C, the
inset graph is the incremental area under the curve. Data presented are
mean 6 SEM. * denotes statistically significant difference between wt
and tpl2
2/2.
doi:10.1371/journal.pone.0039100.g003
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Male wt and tpl2
2/2 mice were housed in a pathogen-free
barrier protected environment on a 12 h:12 h light:dark cycle. All
procedures were approved by the Alfred Medical Research and
Education Precinct (AMREP) animal ethics committee. This study
was specifically approved by the AMREP animal ethics committee
(approval no. E/0861/2009/F). tpl2
2/2 mice were generated as
described previously [12] and were backcrossed more than 12
generations to the C57BL/6 background. C57Bl/6 mice were
used as wt controls. wt and tpl2
2/2 mice were fed either standard
mouse chow diet containing 8% calories from fat, 21% from
protein and 71% from carbohydrate, or a high fat diet containing
either 42% calories from fat, 20% from protein and 35% from
carbohydrate or a high fat diet containing 59% calories from fat,
15% from protein and 26% from carbohydrate (Speciality Feeds,
Glen Forest, Australia). All mice commenced either standard chow
or high fat diets at 8 weeks of age.
Body composition was determined using an EchoMRI body
composition analyzer (Columbus Instruments, OH, USA). Glucose
tolerance tests (GTT) were performed following a 5 h fast. 1 g of
glucoseper kgof leanbodymass, asdeterminedfrom theEchoMRI
analysis, was injected intraperitoneally (IP) and blood glucose
concentrations were determined from blood samples obtained from
atailclip.Bloodglucoseconcentrationsweredeterminedatbaseline
and at 15 minute intervals until 1 h and then at 30 minute intervals
thereafter. Insulin tolerance tests were performed in an analogous
mannertoGTTexceptthat0.75 U(HFdiet)or0.5 U(standardchow
diet) insulin per kg of lean body mass was injected. Blood glucose
concentrations were determined using an ACCU-CHEK glucose
analyzer (Roche). Plasma insulin was determined by enzyme-linked
immunosorbant assay (Millipore).
For Western blotting, approximately 50 mg of white adipose
tissue from the epididymal fat pad was homogenizedin ice coldlysis
buffer containing 50 mM TRIS (pH 7.4), 130 mM NaCl, 5 mM
EDTA, 1% NP-40, 1 mM PMSF, 1 mM NaF, Phosphatase
Inhibitor Cocktail (Containing sodium vanadate, sodium molyb-
date, sodium tartarate, and imidazole; Sigma-Aldrich) and Protease
Inhibitor Cocktail (Containing 4-(2-aminoethyl) benzenesulfonyl
fluoride (AEBSF), pepstatinA, E-64, bestatin, leupeptin, and
aprotinin; Sigma-Aldrich). Following total protein determination
usingtheBCAassay,lysatesweresolubilizedinLaemelli’sbufferand
heated at 95uC for ,5 min. For Western blotting, 20 to 40 mgo f
total protein was resolved by SDS-PAGE and transferred to
Figure 4. wt and tpl2
2/2 mice were fed either standard chow or
42% high fat diet for 16 weeks. mRNA expression was determined
in epididymal adipose tissue depots. Data are expressed as fold change
from wt, standard chow fed mice. Data presented are mean 6 SEM.
(n=5–6). * denotes statistically significant dietary main effect.
C=Standard chow; HF=High Fat.
doi:10.1371/journal.pone.0039100.g004
Figure 5. In (A) and (C) wt and tpl2
2/2 mice were fed either standard chow or 42% high fat diets for 16 weeks. (A) Protein expression
was determined by Western blotting in epididymal adipose tissue depots. (B) Tpl2 mRNA expression was determined in wt mice that were fed a
standard chow (n=13) or 42% high fat (n=15) diet for 12 to 16 weeks from 3 independent experiments. (C) Protein expression was determined by
Western blotting in epididymal adipose tissue depots. N=6 in each group. All data presented are mean 6 SEM. C=Standard chow; HF=High Fat.
doi:10.1371/journal.pone.0039100.g005
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ing transfer, membranes were washed (TBS +0.5% Tween; TBST),
blocked(TBSTcontaining5%skimmilk)andwashedagainpriorto
overnight incubation (4uC) with specific primary antibodies.
Following washing, membranes were incubated with HRP-linked
secondary antibody (GE Healthcare, UK) for 1 hour at room
temperature. After a final wash, membranes were developed using
ECL (GE Healthcare, UK). Phospho-ERK antibody was obtained
from Cell Signaling Technology (cat#9106). Antibodies against
total ERK1/2 (Cat# Sc-94) and Tpl2 (cat# Sc-720) were obtained
from Santa Cruz Biotechnology.
For gene expression analysis, total RNA was extracted from
epididymal fat depots by TRIZOL extraction performed according
to the manufacturer’s instructions. 1.5 mg of RNA was reverse
transcribed according to the manufacturer’s instructions (TaqMan
ReverseTranscriptionReagents;AppliedBiosystems).Expressionof
emr1, itgax, tnf and 18S was determined by real time RT-PCR using
specific primer and probe sets (Assays-on-Demand
TM, Applied
Biosystems). Expression of tpl2 and gapdh were determined using
specific primers (Tpl2 forward 59-CTTGCATTTGCAAAC-
CATGC-39, reverse 59-GGAACAAGGAGAACATCCGA-39;
GAPDH forward 59-TTGGCCGTATTGGGCGCCTG-39, re-
verse59-CACCCTTCAAGTGGGCCCCG-39)anddetectedusing
Fast SYBRGreen(Applied Biosystems).Allsamples weremeasured
in duplicate and data were analysed using the comparative CT
methodandareexpressedasafoldchangefromwtstandardchowfed
animals.
Forhistology,pancreatawerefixed in4%paraformaldehyde, cut
atathicknessof5 mm,mountedonto3-aminopropyltriethoxy-silane
(AES)-coated slides and stained withHematoxylinand Eosin.
All data are expressed as the mean 6 SEM. Westerns Blots were
quantified using Quantity One software. Data was analyzed by
Student’s t-test or ANOVA followed by pairwise comparison
testing (Student Newman Keuls Method) where appropriate, using
SigmaStat Statistical Software Version 3.5. P-values #0.05 were
accepted as statistically significant.
Supporting Information
Figure S1 Pancreatic sections from wt and tpl2
2/2 mice
fed either a standard chow or high fat diet for 16 weeks
were stained with haematoxylin and Eosin. Data is
representative of three mice in each group.
(TIF)
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Figure 6. wt (n=10) and tpl2
2/2 (n=9) mice were fed a 59% high fat diet for 16 weeks. (A) Percentage body fat. (B) Fasting blood glucose.
(C) Fasting plasma insulin. (D) Glucose tolerance test. (E) Insulin tolerance test. In D, the inset graph is the incremental area under the curve. Data
presented are mean 6 SEM. In B and C, * denotes statistically significant difference as determined by Student’s T-test. In D and E, * denotes
statistically significant difference between wt and tpl2
2/2 at indicated time points as determined by 2-way repeated measures ANOVA. Data
presented are mean 6 SEM.
doi:10.1371/journal.pone.0039100.g006
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